SS Innovations International (NASDAQ: SSII), a developer of surgical robotic technologies, announced the promotion of Dr. Vishwa Srivastava to president and the appointment of Gary Lo as chief financial officer. The leadership changes come as the company advances international expansion plans for its SSi Mantra surgical robotic system and addresses regulatory milestones in key markets.
Srivastava, who previously served as CEO of the company’s Asia Pacific operations, will focus on building the U.S. business and leading global operations. Both executives are based in the United States. Lo brings more than three decades of financial leadership experience across technology companies, including the medical technology sector, with expertise in capital markets, financial planning and strategic growth. The appointments signal a push to deepen the company’s presence in the U.S. market while leveraging Srivastava’s regional experience to scale globally. For a company seeking to make robotic surgery more affordable and accessible, having a president dedicated to the U.S. market and a CFO with extensive capital markets experience could be critical in navigating regulatory pathways and pursuing growth initiatives.
The leadership changes come as SS Innovations advances its international expansion plans for the SSi Mantra surgical robotic system. The company is responding to questions from the U.S. Food and Drug Administration regarding its 510(k) premarket notification while pursuing CE marking certification in the European Union. These regulatory steps are essential for market access in two of the world’s largest healthcare markets. SS Innovations is also finalizing a pipeline of additional health care technologies at its research and development facility in India, with plans to introduce them in the coming months. The combination of a strengthened U.S.-based leadership team and a expanding product pipeline positions the company to compete in the global surgical robotics market.
The SSi Mantra surgical robotic system is a modular, multi-arm system with advanced technology features, including 3 to 5 modular robotic arms, an open-faced ergonomic surgeon command center, a large 3D 4K monitor, and the ability for superimposition of 3D models of diagnostic imaging. The optional SSi MantrAsana tele-surgeon console is a portable, compact alternative that enables enhanced portability, ergonomic flexibility, and telesurgery capability. The system utilizes over 40 different types of robotic endo-surgical instruments to support different specialties, including cardiac surgery, and 5mm instruments for the pediatric population and ENT surgeries. The SSi Mantra has been clinically validated in India in more than 190 different types of surgical procedures. For more information, visit the company’s website at ssinnovations.com or its LinkedIn page. The latest news and updates relating to SSII are available in the company’s newsroom at https://ibn.fm/SSII.
The leadership appointments and regulatory progress are important because they signal the company’s commitment to entering the U.S. market and expanding globally. With Srivastava focusing on the U.S. business and Lo bringing financial expertise, SS Innovations aims to navigate the FDA process and European certification while continuing to innovate. The company’s vision to make robotic surgery affordable and accessible could disrupt the surgical robotics landscape, which is currently dominated by costly systems. As SS Innovations works to introduce additional technologies from its India R&D facility, the strengthened leadership team will be crucial in executing its growth strategy and delivering value to shareholders and patients.


